Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03234712
Other study ID # M16-438
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date October 10, 2017
Est. completion date April 14, 2021

Study information

Verified date May 2021
Source AbbVie
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, Phase 1, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-321 for participants with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). The study will consist of 2 phases: Dose Escalation Phase and Expansion Phase.


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date April 14, 2021
Est. primary completion date April 14, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. - Histologically or cytologically confirmed solid tumor of one of the following types associated with overexpression of Epidermal Growth Factor Receptor (EGFR). (For Expansion Phase: Subjects must have EGFR overexpression demonstrated by central assessment or Sponsor selected test). Dose Escalation Phase: - Colorectal cancer (CRC), Glioblastoma (GBM), squamous cell carcinoma of the head and neck (HNSCC), non-small cell lung cancer (NSCLC), bladder, cervical, esophageal, kidney or sarcoma. - Participants must have disease that has progressed on prior treatment and is not amenable to surgical resection or other approved therapeutic options with curative intent. Participants must not be eligible for, or has refused further therapy that is likely to provide a survival benefit. - Must have measureable disease as per RECIST Version 1.1 or RANO (for GBM). - Minimum life expectancy of at least 12 weeks. Expansion Phase (Solid Tumor Cohort): - Histologically or cytologically confirmed advanced solid tumor. - Participants must have disease that has progressed on prior treatment and is not amenable to surgical resection or other approved therapeutic options with curative intent. - Must have measureable disease as per RECIST Version 1.1. - Minimum life expectancy of at least 12 weeks. Expansion Phase (GBM Cohort Only): - Participant has recurrent primary (de novo) glioblastoma histologically confirmed at any time from initial diagnosis through latest recurrence. - Participant has recurrent GBM per Response Evaluation in Neuro-Oncology (RANO) requirements. - Tumor is measurable according to RANO criteria. Exclusion Criteria: - Active uncontrolled infection National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE Grade greater than or equal to 3). - New York Heart Association (NYHA) Class III or IV heart failure and/or ejection fraction of < 40% as measured by echocardiogram at screening. - Unstable angina pectoris or cardiac ventricular arrhythmia. - Myocardial infarction or cerebrovascular accident (CVA) within 6 months. - Documented history of capillary leak syndrome within 6 months of study enrollment. - Grade 2 or higher peripheral edema, ascites, pleural, or pericardial effusion within 4 weeks of study enrollment or any history of recurrent grade 2 or higher effusions requiring ongoing drainage. - Active keratitis or current corneal disorder. - Laser-assisted in situ keratomileusis (LASIK) procedure within the last 1 year or cataract surgery within the last 3 months. - Major surgery (including opening of the abdomen, chest) within 21 days of the first dose of study drug. - Uncontrolled metastases from an extracranial solid tumor to the central nervous system (CNS). Participants with brain metastases from an extracranial solid tumor are eligible after definitive therapy provided they are asymptomatic for at least 2 weeks prior to first dose of ABBV-321. - No history of medical condition resulting in nephrotic range proteinuria. - Participants must not have been treated in anticancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal therapy, biologic therapy or investigational anti-cancer therapy within a period of 21 days or herbal anticancer therapy within 7 days prior to the first dose of study drug. - For approved targeted small molecules, a washout period of 5 half-lives is adequate (no washout period required for subjects currently on erlotinib) - Participant must not have been in more than three lines of systemic cytotoxic therapy (excluding adjuvant and neoadjuvant therapy)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ABBV-321
Intravenous infusion

Locations

Country Name City State
Australia Monash Health /ID# 217435 Clayton Victoria
Australia Austin Hospital /ID# 166137 Heidelberg Victoria
Australia Northern Cancer Institute /ID# 166138 St Leonards New South Wales
Israel Sheba Medical Center /ID# 166398 Ramat Gan
United States Dana-Farber Cancer Institute /ID# 212920 Boston Massachusetts
United States Northwestern University Feinberg School of Medicine /ID# 165191 Chicago Illinois
United States University of Chicago /ID# 166064 Chicago Illinois
United States Duke University Medical Center /ID# 166135 Durham North Carolina
United States University of Kentucky Markey Cancer Center /ID# 217665 Lexington Kentucky
United States The Angeles Clinic and Researc /ID# 166133 Los Angeles California
United States Columbia Univ Medical Center /ID# 167184 New York New York
United States Lifespan Cancer Institute at Rhode Island Hospital /ID# 168600 Providence Rhode Island
United States University of California, Davis Comprehensive Cancer Center /ID# 215012 Sacramento California
United States Washington University-School of Medicine /ID# 214955 Saint Louis Missouri
United States South Texas Accelerated Research Therapeutics /ID# 166134 San Antonio Texas
United States Northshore University Health System Dermatology Clinical Trials Unit /ID# 201095 Skokie Illinois
United States Highlands Oncology Group /ID# 166132 Springdale Arkansas
United States Stony Brook University Hospital /ID# 216976 Stony Brook New York

Sponsors (1)

Lead Sponsor Collaborator
AbbVie

Countries where clinical trial is conducted

United States,  Australia,  Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary AUCt for ABBV-321 Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Measurable Concentration (AUCt) for ABBV-321 Up to 78 days post dose
Primary AUC8 for ABBV-321 AUC8 is the area under the plasma concentration-time curve from Time 0 to infinite time. Up to 78 days post dose
Primary Tmax of ABBV-321 Time to Cmax (Tmax) of ABBV-321 Up to 78 days post dose
Primary Terminal phase elimination rate constant (ß) for ABBV-321 Terminal phase elimination rate constant (ß) Up to 78 days post dose
Primary Cmax of ABBV-321 Maximum observed plasma concentration (Cmax) of ABBV-321 Up to 78 days post dose
Primary Dose Escalation Phase: Recommended Phase 2 dose (RPTD) for ABBV-321 The RPTD will be determined using available safety and pharmacokinetics data upon completion of the Dose Escalation Phase Minimum first cycle of dosing (up to 28 days)
Primary t1/2 for ABBV-321 Terminal elimination half-life (t1/2) Up to 78 days post dose
Primary Dose Escalation Phase: Maximum tolerated dose (MTD) of ABBV-321 The MTD of ABBV-321 will be determined during the dose escalation phase of the study. Minimum first cycle of dosing (up to 28 days)
Secondary Progression-Free Survival (PFS) PFS is defined as the number of days from the first dose date to the earliest date of disease progression per RECIST 1.1 or RANO criteria or death, whichever occurred first. Up to approximately 5 years
Secondary Duration of Response (DOR) DOR for a given participant is defined as the number of days from the day CR or PR (whichever is recorded first) occurred to the earliest date of disease progression per RECIST 1.1 or RANO criteria or death, whichever occurred first. Up to approximately 5 years
Secondary Disease Control Rate (DCR) DCR is defined as the proportion of participants with objective evidence of complete response (CR), partial response (PR) or stable disease (SD); a participants best overall response assignment of SD must be maintained for at least 6 weeks since the first dose date of study drug. Up to 5 years
Secondary Time to progression (TTP) TTP is defined as the number of days from the first dose date to the earliest date of disease progression per RECIST version 1.1 or RANO criteria. Up to approximately 5 years
Secondary Change from Baseline in QTcF QT interval measurement corrected by Fridericia's formula (QTcF) change from baseline Up to 61 days post dose
Secondary Overall Survival (OS) OS is defined as number of days from the date of the first dose to the date of death for all dosed participants. For participants who are not deceased, the data will be censored at the last known date to be alive. Up to approximately 5 years
Secondary Objective response rate (ORR) ORR is defined as the proportion of participants with a response of partial response (PR) or better; Response Assessment in Neuro-Oncology (RANO) criteria will be used for glioblastoma (GBM) participants, and Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria will be used for all other participants. Up to 5 years
See also
  Status Clinical Trial Phase
Completed NCT03311477 - A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors Phase 1
Completed NCT02955251 - A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors Phase 1
Completed NCT03071757 - A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT04417465 - First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors Phase 1
Terminated NCT03145909 - A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR) Phase 1
Completed NCT04196283 - A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Phase 1
Active, not recruiting NCT02099058 - A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors Phase 1
Active, not recruiting NCT04721015 - Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors Phase 1
Active, not recruiting NCT02988960 - A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT03821935 - Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05929235 - A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma Phase 1